Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
Date:5/26/2012

amilial hypercholesterolemia is a common, serious, and often undiagnosed cause of early heart disease. There remains a high degree of unmet need in these patients as a large percentage are unable to reach optimal LDL-C goals despite being on maximal lipid-lowering therapy," said Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of the study. "These data suggest that SAR236553/REGN727 may provide a new option, on top of existing therapies, to lower LDL-cholesterol and finally reach LDL-C goals for these difficult-to-treat patients."

Sanofi and Regeneron also announced today that based on discussions with the U.S. and European regulatory authorities, they intend to initiate a global Phase 3 program with SAR236553/REGN727 in June. This will be the first Phase 3 program of an investigational drug targeting PCSK9.

"These data, along with recently presented data in patients with hypercholesterolemia, further support our belief that blocking PCSK9 with our antibody has the potential to offer a novel mechanism for lowering LDL-cholesterol in a broad range of patients," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. Dr. Elias Zerhouni, President, Global Research & Development, Sanofi, added: "Our global Phase 3 program will include patients with high unmet medical need, such as patients with familial hypercholesterolemia or with elevated cardiovascular risk who cannot reach their LDL-cholesterol goals with current standard therapies. The program reflects our excitement and commitment to develop this potential therapeutic option for these patients."

About PCSK9

PCSK9 is known to be a determinant of circulating LDL-C levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-C from the blood.['/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
2. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
3. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
4. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
5. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
6. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
7. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
8. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
9. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... ONOM@TOPIC and SilOnIS shared the ... most innovative and sustainable project in the ... smartcard platform for,citizenship and mobile multimedia applications ... for users,while adding value for network operators. ...
... Investor Update Conference Call Set for March 7, ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,it has entered into ... the privately-held specialty pharmaceuticals marketer which,Senetek licensed in ...
... 4 Osteotech, Inc.,(Nasdaq: OSTE ), a ... for,regenerative medicine, announced today that the Food and ... its Plexur,M(TM) Biocomposite. Adapting the Company,s proprietary Plexur(R),Technology, ... bony voids or gaps,of the skeletal system that ...
Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Senetek PLC in Dispute With Marketer of Pyratine-6(TM) 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 3
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... University of Nottingham have taken some important first steps ... a leading science journal reports. Dr Cameron Alexander ... of Pharmacy have used polymers long-chain molecules ... surfaces of a real cell. In work published ...
... by clean, local-source energy. Faster, more reliable technologies ... language. Medical care tailored to your DNA, or ... diseases and injuries. Five University of Pittsburgh ... health, and technology as part of Faculty Early ...
... Researchers from Weill Cornell Medical College may have discovered ... the world,s most common blood disorders, beta-thalassemia, commonly known ... is the most commonly inherited disease in the world, ... of every 100,000 African-Americans. The World Health Organization estimates ...
Cached Biology News:Life, but not as we know it? 2Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 2Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 3Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 4
... DNA polymerase obtained by high level expression ... E. coli, Concentration: 5U/ul, Applications: Standard PCR ... the world leader in serving science. Thermo ... world healthier, cleaner and safer by providing ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: